                         SEQUENCE LISTING

<110>  Novo Nordisk A/S
 
<120>  GLP-1 AGONISTS

<130>  8463.204-WO

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein


<220>
<221>  MISC_FEATURE
<222>  (1)..(40)
<223>  For "X" amino acid residues, see definition hereof in the patent 
       application

<400>  1

Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Xaa Ser Xaa Xaa Xaa Glu Xaa 
1               5                   10                  15      


Xaa Ala Xaa Xaa Xaa Phe Ile Xaa Trp Leu Xaa Xaa Xaa Xaa Xaa Xaa 
            20                  25                  30          


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  40  


<210>  2
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Protein


<220>
<221>  MISC_FEATURE
<222>  (1)..(32)
<223>  For "X" amino acid residues, see definition hereof in the patent 
       application

<400>  2

Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Xaa Tyr Leu Glu Xaa 
1               5                   10                  15      


Xaa Ala Ala Xaa Glu Phe Ile Xaa Trp Leu Val Xaa Xaa Xaa Xaa Xaa 
            20                  25                  30          


<210>  3
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein

<400>  3

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 
1               5                   10                  15      


Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser 
        35                  


<210>  4
<211>  44
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein

<400>  4

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 
1               5                   10                  15      


Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys 
        35                  40                  


<210>  5
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Side chain, as defined in the patent application, attached to K

<400>  5

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa Arg Lys 
            20                  25                  30      


<210>  6
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  side chain, as defined in the patent application, attached to K

<400>  6

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 
            20                  25                  30      


<210>  7
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Aib

<400>  7

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa Arg 
            20                  25                  30  


<210>  8
<211>  60
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein


<220>
<221>  MISC_FEATURE
<222>  (1)..(60)
<223>  genetically fused to human albumin

<400>  8

His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg His Gly 
            20                  25                  30          


Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln Ala 
        35                  40                  45              


Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 
    50                  55                  60  


<210>  9
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein


<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  = P or Y

<400>  9

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 
1               5                   10                  15      


Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Xaa 
            20                  25                  30      


<210>  10
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  protein


<220>
<221>  MISC_FEATURE
<222>  (2)..(3)
<223>  = SD (exendin-3) or GE (exendin-4)

<400>  10

His Xaa Xaa Gly Thr Phe Ile Thr Ser Asp Leu Ser Lys Gln Met Glu 
1               5                   10                  15      


Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro 
            20                  25                  30          


Ser Ser Gly Ala Pro Pro Pro Ser 
        35                  40  


